Payment overview · 2025
General Payments
$1,879.50
91 reported records · 30 companies
Healthcare provider profile · identity verified
Clement Aluyi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PULASKI, TN · NPI 1447459607
Verified facts
What the public records show
CMS Open Payments records show Clement Aluyi, M.D. received $1,879.50 in general payments during 2025 across 91 reported records.
ABBVIE INC. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Creon, Farxiga, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Trelegy Ellipta, Ubrelvy, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $358.89 | 19.1% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $211.69 | 11.3% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $211.05 | 11.2% | 10 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $92.44 | 4.9% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $89.12 | 4.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.71 | 4.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.79 | 3.9% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $71.97 | 3.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.83 | 3.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.40 | 3.4% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $61.24 | 3.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.19 | 3.1% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $40.83 | 2.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.68 | 2.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$37.16 | 2.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.21 | 1.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.50 | 1.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.81 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.16 | 1.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.30 | 1.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.90 | 1.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $20.86 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.29 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.96 | 1.1% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $19.00 | 1.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.11 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.87 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.54 | 0.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.61 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.39 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,879.50 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $211.05 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $145.20 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $133.60 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $132.98 | 6 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $120.68 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $109.45 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $92.44 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $71.97 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $71.97 | 3 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $69.55 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $64.40 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.76 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.76 | 4 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $61.24 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.37 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $53.75 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $41.55 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $40.83 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.21 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 312 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 131 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 31 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 197 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 133 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 35 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
131 | 46 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
312 | 99 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
181 | 58 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
133 | 41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
181 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | 18 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
61 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
197 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
61 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1054 | 200 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 598 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 196 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 503 | 177 |
| Alprazolam | Alprazolam | 500 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 485 | 107 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 419 | 78 |
| Lisinopril | Lisinopril | 408 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 99 |
| Tizanidine Hcl | Tizanidine Hcl | 314 | 94 |
| Farxiga | Dapagliflozin Propanediol | 312 | 99 |
| Pregabalin | Pregabalin | 305 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 118 |
| Omeprazole | Omeprazole | 287 | 120 |
| Diclofenac Sodium | Diclofenac Sodium | 248 | 98 |
| Zolpidem Tartrate | Zolpidem Tartrate | 244 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 116 |
| Furosemide | Furosemide | 200 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 73 |
| Ozempic | Semaglutide | 197 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 67 |
| Carvedilol | Carvedilol | 193 | 73 |
| Trazodone Hcl | Trazodone Hcl | 189 | 68 |
| Jardiance | Empagliflozin | 181 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 62 |
| Ondansetron Hcl | Ondansetron Hcl | 167 | 56 |
| Losartan Potassium | Losartan Potassium | 158 | 63 |
| Metformin Hcl | Metformin Hcl | 148 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 133 | 41 |
| Buspirone Hcl | Buspirone Hcl | 132 | 45 |
| Linzess | Linaclotide | 131 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 130 | 24 |
| Promethazine Hcl | Promethazine Hcl | 128 | 26 |
| Eszopiclone | Eszopiclone | 121 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 49 |
| Potassium Chloride | Potassium Chloride | 107 | 50 |
| Clonazepam | Clonazepam | 104 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 104 | 36 |
| Prednisone | Prednisone | 104 | 66 |
| Simvastatin | Simvastatin | 104 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 39 |
| Glipizide | Glipizide | 103 | 37 |
| Lovastatin | Lovastatin | 100 | 37 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 97 | 12 |
| Baclofen | Baclofen | 94 | 30 |
| Sertraline Hcl | Sertraline Hcl | 94 | 31 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 93 | 27 |
| Eliquis | Apixaban | 91 | 31 |
| Meclizine Hcl | Meclizine Hcl | 91 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 26 |
| Diazepam | Diazepam | 89 | 26 |
| Ibuprofen | Ibuprofen | 86 | 33 |
| Allopurinol | Allopurinol | 82 | 25 |
| Fluconazole | Fluconazole | 81 | 40 |
| Rizatriptan | Rizatriptan Benzoate | 78 | 25 |
| Kerendia | Finerenone | 75 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 30 |
| Famotidine | Famotidine | 73 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 25 |
| Celecoxib | Celecoxib | 69 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 19 |
| Meloxicam | Meloxicam | 68 | 35 |
| Mirtazapine | Mirtazapine | 67 | 20 |
| Montelukast Sodium | Montelukast Sodium | 67 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 17 |
| Ondansetron Odt | Ondansetron | 66 | 31 |
| Sucralfate | Sucralfate | 65 | 26 |
| Topiramate | Topiramate | 65 | 23 |
| Chlorthalidone | Chlorthalidone | 63 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 35 |
| Methocarbamol | Methocarbamol | 62 | 22 |
| Donepezil Hcl | Donepezil Hcl | 61 | 17 |
| Nifedipine Er | Nifedipine | 61 | 24 |
| Rexulti | Brexpiprazole | 61 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 60 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 23 |
| Buprenorphine Hcl | Buprenorphine Hcl | 59 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 19 |
| Atenolol | Atenolol | 57 | 15 |
| Xarelto | Rivaroxaban | 57 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 25 |
| Primidone | Primidone | 56 | 14 |
| Metformin Hcl Er | Metformin Hcl | 53 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 44 |
| Lamotrigine | Lamotrigine | 52 | 12 |
| Alendronate Sodium | Alendronate Sodium | 49 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 20 |
| Tramadol Hcl | Tramadol Hcl | 49 | 16 |
| Trulicity | Dulaglutide | 49 | 18 |
| Levetiracetam | Levetiracetam | 48 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 16 |
| Clonidine Hcl | Clonidine Hcl | 46 | 15 |
| Mounjaro | Tirzepatide | 46 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 34 |
| Azithromycin | Azithromycin | 42 | 35 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 14 |
| Irbesartan | Irbesartan | 38 | 13 |
| Propranolol Hcl | Propranolol Hcl | 36 | 12 |
| Glipizide Er | Glipizide | 35 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Ubrelvy | Ubrogepant | 35 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 17 |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 35 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | 11 |
| Spironolactone | Spironolactone | 34 | 16 |
| Valsartan | Valsartan | 34 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | 12 |
| Glimepiride | Glimepiride | 33 | 12 |
| Levemir Flexpen | Insulin Detemir | 33 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Colchicine | Colchicine | 32 | 17 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | 29 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | 14 |
| Methylprednisolone | Methylprednisolone | 31 | 30 |
| Nurtec Odt | Rimegepant Sulfate | 31 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 14 |
| Aripiprazole | Aripiprazole | 30 | 17 |
| Emgality Pen | Galcanezumab-Gnlm | 30 | suppressed |
| Estradiol | Estradiol | 30 | 11 |
| Megestrol Acetate | Megestrol Acetate | 30 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 12 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Finasteride | Finasteride | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | 11 |
| Mupirocin | Mupirocin | 27 | 20 |
| Divalproex Sodium | Divalproex Sodium | 26 | 11 |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 11 |
| Temazepam | Temazepam | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | 12 |
| Digoxin | Digoxin | 24 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | 13 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Nystatin | Nystatin | 22 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 15 | 11 |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Caplyta | Lumateperone Tosylate | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | 11 |
| Indapamide | Indapamide | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,879.50 · 91 records | ABBVIE INC. | AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, COBENFY, CREON, Cologuard Collection Kit, FANAPT, FARXIGA, GVOKE HYPOPEN, HETLIOZ, INCEPTIV, JOURNAVX, Korlym, LINZESS, LYBALVI, MAVYRET, MINIMED 780G, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Omnipod, Ozempic, QULIPTA, QUTENZA, REPATHA, REXULTI, SUBLOCADE, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN Access System, XIFAXAN, YUPELRI, ZENPEP, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error